campesterol has been researched along with Dyslipidemias in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arasaki, O; Chihara, A; Morimoto, T; Node, K; Nomiyama, T; Sakuma, M; Shimabukuro, M; Tanaka, A; Ueda, S | 1 |
| Cofán, M; Forga, MT; Larrousse, M; Leyes, P; Martínez, E; Pérez-Heras, AM; Ros, E; Trabal, J | 1 |
| Kanno, K; Kishikawa, N; Mizooka, M; Sugiyama, A; Tazuma, S; Yokobayashi, K | 1 |
| Hattori, S; Hattori, Y | 1 |
| Lupattelli, G; Mannarino, E; Mannarino, MR; Pirro, M; Roscini, AR; Schillaci, G; Siepi, D | 1 |
| De Vuono, S; Lupattelli, G; Mannarino, E | 1 |
| Athias, A; Beacco, M; Bouillet, B; Brindisi, MC; Cercueil, JP; Duvillard, L; Guiu, B; Hillon, P; Petit, JM; Rollot, F; Verges, B | 1 |
1 review(s) available for campesterol and Dyslipidemias
| Article | Year |
|---|---|
Patterns of cholesterol metabolism: pathophysiological and therapeutic implications for dyslipidemias and the metabolic syndrome.
Topics: Biomarkers; Cholestanol; Cholesterol; Dyslipidemias; Humans; Lipid Metabolism; Metabolic Syndrome; Phytosterols; Sitosterols | 2011 |
1 trial(s) available for campesterol and Dyslipidemias
| Article | Year |
|---|---|
Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.
Topics: Aged; Biomarkers; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Phytosterols; Pyrimidines; Sitagliptin Phosphate; Sitosterols; Time Factors; Treatment Outcome | 2019 |
5 other study(ies) available for campesterol and Dyslipidemias
| Article | Year |
|---|---|
Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; HIV Infections; Humans; Lipid Metabolism; Male; Middle Aged; Phytosterols; Protease Inhibitors | 2014 |
Long-term administration of a Niemann-Pick C1-like 1 inhibitor, ezetimibe, does not worsen bile lithogenicity in dyslipidemic patients with hepatobiliary diseases.
Topics: Anticholesteremic Agents; Bile; Cholesterol; Dyslipidemias; Ezetimibe; Fatty Liver; Female; Gallstones; Humans; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Phytosterols; Ursodeoxycholic Acid | 2016 |
Efficacy and safety of ezetimibe in patients undergoing hemodialysis.
Topics: Aged; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol; Dyslipidemias; Ezetimibe; Female; Glycated Hemoglobin; Humans; Linear Models; Male; Middle Aged; Phytosterols; Renal Dialysis; Renal Insufficiency; Triglycerides | 2010 |
Visceral fat positively correlates with cholesterol synthesis in dyslipidaemic patients.
Topics: Adult; Body Fat Distribution; Body Mass Index; Cholesterol; Chromatography, Gas; Dyslipidemias; Female; Humans; Intra-Abdominal Fat; Male; Mass Spectrometry; Middle Aged; Phytosterols; Sitosterols; Statistics as Topic; Ultrasonography; Waist Circumference | 2012 |
Liver fat content is associated with an increase in cholesterol synthesis independent of statin therapy use in patients with type 2 diabetes.
Topics: Aged; Biomarkers; Cholesterol; Diabetes Mellitus, Type 2; Dyslipidemias; Fatty Liver; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Liver; Magnetic Resonance Spectroscopy; Male; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Phytosterols; Risk Factors; Sitosterols; Treatment Outcome | 2012 |